

Spironolactone does not prevent atrial fibrillation in patients with heart failure with preserved ejection fraction: post hoc analysis of the randomized, placebo controlled TOPCAT trial


Jolien Neefs MD, Nicoline W.E. van den Berg MD, Sébastien P.J. Krul, MD, PhD, S. Matthijs Boekholdt, MD, PhD, Joris R. de Groot MD, PhD

Address for correspondence:

J.R. de Groot, MD, PhD
Department of Cardiology
Amsterdam UMC, University van Amsterdam
Meibergdreef 9, 1105 AZ Amsterdam
T: +3120-5661409
E: j.r.degroot@amc.uva.nl

Online Figure 1. Forest plot of the hazard ratios of the risk of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure in either patients with a history of AF at baseline.


	HR	95% CI	p	Cases
Primary endpoint	0.87	0.71 1.07	0.18	369/2,228
CVD Death	0.84	0.63 1.12	0.23	184/2,228
Aborted Cardiac arrest	0.50	0.09 2.72	0.42	6/2,228
Hospitalization for HF	0.79	0.62 1.02	0.08	240/2,228
Death from any cause	0.89	0.71 1.12	0.34	292/2,228
Hospitalization for any cause	0.95	0.83 1.08	0.42	882/2,228
Myocard infarction	0.80	0.52 1.23	0.31	83/2,228
Stroke	0.86	0.51 1.45	0.57	56/2,228



CVD cardiovascular disease, *HF* heart failure


Online Figure 2. Forest plot of the hazard ratios of the risk of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure in either patients without a history of AF at baseline.

	HR	95% CI	p	Cases
Primary endpoint	1.26	0.87 1.84	0.22	112/505
CVD Death	1.30	0.75 2.25	0.36	52/505
Aborted Cardiac arrest	N/A	N/A N/A	N/A	1/505
Hospitalization for HF	1.18	0.74 1.88	0.48	72/505
Death from any cause	1.21	0.78 1.87	0.39	82/505
Hospitalization for any cause	1.02	0.81 1.29	0.84	288/505
Myocard infarction	1.01	0.46 2.20	0.99	25/505
Stroke	1.61	0.64 4.10	0.32	19/505




CVD cardiovascular disease, HF heart failure

Online Figure 3. Subgroup analyses of the hazard ratios of new-onset atrial fibrillation according to subgroups pre-specified in the main TOPCAT publication.



BMI body mass index, *eGFR* estimated glomerular filtration rate, *NYHA* New York Heart Association, *SBP* systolic blood pressure.

Online Figure 4. Subgroup analyses of the hazard ratios of recurrence of atrial fibrillation according to subgroups pre-specified in the main TOPCAT publication.



BMI body mass index, *eGFR* estimated glomerular filtration rate, *NYHA* New York Heart Association, *SBP* systolic blood pressure.